Participant flow

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma · Source last updated 2016-10-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Vandetanib 300 mg/day oral

   id

   FG000

   title

   Vandetanib

2. description

   Vinorelbine 30 mg/m2 iv, administrated weekly

   id

   FG001

   title

   Vinorelbine

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         2

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Physician Decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Death

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Lost to Follow-up

   6. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         6

      type

      Progressive disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. comment

         Randomised patients ongoing study treatment at data cut-off

         group Id

         FG000

         num Subjects

         0

      2. comment

         Randomised patients ongoing study treatment at data cut-off

         group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

First subject enrolled: 17 December 2007, Last subject last visit: 22 July 2009. The study was conducted at 2 centres in Switzerland and 4 centres in Germany.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice